Drug Trial Radar · NCT06517875
Study of Momelotinib in Combination With Luspatercept in Participants With Transfusion Dependent Myelofibrosis
Last checked: Nov 20, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
68
Planned (sponsor's estimate)
Start
Feb 28, 2025
Primary completion
Mar 16, 2027
Study completion Jan 31, 2029
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- First posted
- Jul 24, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this Phase 2 study is to evaluate the efficacy and safety of momelotinib (MMB) in combination with luspatercept (LUSPA) in participants with transfusion dependence (TD) primary myelofibrosis (PMF) or Post-polycythemia vera (PV)/ essential thrombocythemia (ET) myelofibrosis (MF) who are either janus kinase (JAK) inhibitor (JAKi) naïve or experienced.
Conditions
- Primary Myelofibrosis
- Myelofibrosis; Primary Myelofibrosis; Post-polycythemia Vera Myelofibrosis; Post-essential Thrombocythemia Myelofibrosis
Interventions
MomelotinibDrug
Momelotinib will be administered orally.
LuspaterceptDrug
Luspatercept will be administered subcutaneously.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with TI Response by Week 24Time frame: Up to Week 24
Locations
33 sites in 6 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Ann Arbor, Michigan · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Nashville, Tennessee · Recruiting
GSK Investigational Site
Houston, Texas · Recruiting
GSK Investigational Site
Seattle, Washington · Recruiting
GSK Investigational Site
Vancouver, British Columbia, Canada · Recruiting
GSK Investigational Site
Toronto, Ontario, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Montreal, Quebec, Canada · Recruiting
GSK Investigational Site
Angers, France · Recruiting
GSK Investigational Site
Brest, France · Recruiting
GSK Investigational Site
Nice, France · Recruiting
GSK Investigational Site
Nîmes, France · Recruiting
GSK Investigational Site
Paris, France · Recruiting
GSK Investigational Site
Poitiers, France · Recruiting
GSK Investigational Site
Lyon, Rhône, France · Recruiting
GSK Investigational Site
Lübeck, Germany · Recruiting
GSK Investigational Site
Mannheim, Germany · Recruiting
GSK Investigational Site
Essen, North Rhine-Westphalia, Germany · Recruiting
GSK Investigational Site
Jena, Thuringia, Germany · Recruiting
GSK Investigational Site
Bologna, Italy · Recruiting
GSK Investigational Site
Catania, Italy · Recruiting
GSK Investigational Site
Florence, Italy · Recruiting
GSK Investigational Site
Meldola FC, Italy · Recruiting
GSK Investigational Site
Roma, Italy · Recruiting
GSK Investigational Site
Milan, MI, Italy · Recruiting
GSK Investigational Site
Badalona, Spain · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
Las Palmas, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Madrid, Spain · Recruiting
GSK Investigational Site
Málaga, Spain · Recruiting
GSK Investigational Site
Valencia, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.